Regular researcher at the CHU de Québec Research Center, and professor in the Department of Psychiatry-Neurosciences, Dr. Guertin’s work focuses on paralysis. He discovered a pharmacological treatment called Spinalon that can powerfully activate the locomotor neurons of the spinal cord in paraplegic animals, despite complete injury. This discovery is patented and clinical trials (phase I-IIa) in humans have been successfully completed. This important advance was highlighted in various reports, notably on Radio-Canada television and radio.
Improve the quality of life of people with health problems related to reduced mobility and paralysis
Studies in Dr. Guertin’s lab indicate that, following a spinal cord injury, the spinal neural circuits on either side of the lesion remain ‘alive’, but undergo many modifications at the cellular and intracellular level. Intrinsic properties are studied, as well as ‘plasticity’ type changes in cell genetics and the organization of neural networks. Secondary problems also occur in other biological systems of the body (metabolic, cardiovascular, muscular, dermatological, digestive, etc.) mainly related to mobility impairment and its effects on the metabolism in general. Dr. Guertin’s long-term goal is to develop methods, including pharmacological treatments able to prevent these various changes at the neuronal and systemic and metabolic level to improve these individual’s various physical functions.
Develop treatments capable of restoring functions in the locomotor, reproductive, dermatological and eliminatory systems
To better understand the systems that need to be pharmacologically reactivated or modulated, he is currently studying transmembrane receptors in the spinal cord of the lumbar region. Certain receptor subfamilies seem to be of interest, because they are involved in the actual genesis of several so-called stereotyped functions controlled by the spinal cord – walking, urination, defecation, and ejaculation. In parallel, he is working on optimizing a new treatment aimed at automatically inducing ejaculation in subjects with anejaculation, in relation to lesions of the central nervous system.
2705, boulevard Laurier
Canada G1V 4G2
Data not available
Tonic and Rhythmic Spinal Activity Underlying Locomotion.Journal Article
Curr Pharm Des, 23 (12), pp. 1753-1763, 2017, ISSN: 1381-6128.
Editorial: Spinal Locomotor SystemsJournal Article
Curr Pharm Des, 23 (12), pp. 1721, 2017, ISSN: 1381-6128.
Cardiovascular disease and cancer associated with neurological problems: Some hope for innovative combinatorial approachesJournal Article
Global drugs and therapeutics, 2 (4), pp. 1-2, 2017, ISSN: 2399-9098.
The Human Central Pattern Generator for Locomotion.Journal Article
Neuroscientist, pp. 1073858417699790, 2017, ISSN: 1073-8584.
Chemotheray-induced cardiotoxicity: A major underestimated unmet medical needJournal Article
Global drugs and therapeutics, 2 (3), pp. 1-2, 2017, ISSN: 2399-9098.
- A key subset of receptors involved in spinal-mediated biological rhythms., Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2016-04-01 to 2021-03-31
- Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Development of a first-in-class drug against ejaculatory disorders, Subvention, Instituts de recherche en santé du Canada, Volet Projet: Concours pilotes, from 2016-07-01 to 2018-06-30